Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2018
August 2018, Vol 8, No 8
August 2018, Vol 8, No 8
Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details
By
Phoebe Starr
Breast Cancer
Read More ›
Top 4 Trends That Are Changing Oncology Practices
By
Gail Thompson
Practice Management
What are the most noteworthy trends that can affect an oncology practice’s strategic planning, budgeting, and bottom line? The Association of Community Cancer Centers (ACCC) partnered with the Advisory Board Company to identify some of those trends in the 2017 Trending Now in Cancer Care Survey. The survey results were presented at the 2018 ACCC Annual Meeting & Cancer Center Business Summit.
Read More ›
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
By
Meg Barbor, MPH
Quality Care
,
Practice Management
Opioids are the mainstay treatment for cancer pain, but managing the opioid crisis in the United States requires an “all hands on deck” approach, according to Tonya Edwards, MS, MSN, FNP-C, Nurse Practitioner, Palliative Care and Rehabilitation Medicine, M.D. Anderson Cancer Center, Houston, TX.
Read More ›
CLL11 Study: 5-Year Results Confirm Obinutuzumab plus Chemotherapy as Front-Line Therapy for Patients with Chronic Lymphocytic Leukemia
By
Walter Alexander
2018 EHA Congress Highlights
Read More ›
Once-Weekly Carfilzomib for Patients with Relapsed or Refractory Multiple Myeloma Improves Progression-Free Survival
By
Walter Alexander
2018 EHA Congress Highlights
Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress.
Read More ›
Next-Generation Sequencing More Cost-Effective Than Single-Gene Testing
By
Phoebe Starr
Genomic Testing
Genomic testing is now the standard of care for patients with non–small-cell lung cancer (NSCLC). The 4 identified genomic mutations that are targetable with FDA-approved therapies include
EGFR
,
ALK
,
ROS1
, and
BRAF
, and other NSCLC-associated genetic mutations are targetable with therapies currently being investigated in clinical trials. More genetic mutations are linked to NSCLC, but there is currently no accepted standard for genomic testing in NSCLC, or the optimal timing of such tests.
Read More ›
IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer
By
Wayne Kuznar
Genomic Testing
A new retrospective analysis presented at ASCO 2018 lends support to precision medicine in cancer. In the Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT) clinical trial, selecting a targeted therapy based on patients’ tumor molecular analyses independently predicted longer overall survival (OS) compared with nonmatched therapy across a diverse set of advanced tumor types.
Read More ›
Best Practices: Use of Biomarkers in the Treatment of Patients with Lung Cancer
By
Roy S. Herbst, MD, PhD
;
David L. Rimm, MD, PhD
2018 ASCO Highlights
,
Biomarkers
,
Interview with the Innovators
At ASCO 2018,
Oncology Practice Management
(
OPM
) spoke with Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research at Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT, and David L. Rimm, MD, PhD, Professor of Pathology, Yale University School of Medicine, about the increasing role of biomarkers in the management of patients with lung cancer.
Read More ›
Kymriah Approved for Adults with Relapsed or Refractory Large B-Cell Lymphoma
FDA Approvals, News & Updates
Read More ›
Tafinlar-Mekinist Combination Approved for Metastatic Thyroid Cancer with BRAF V600E Mutation
FDA Approvals, News & Updates
Read More ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
2023 Spotlight: Amgen
3.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes